Allogeneic adipose-derived stem cells not checked
Celltex Therapeutics Corporation
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue”In the company’s words, NCT05017298 on ClinicalTrials.gov
- Tested for
- Corona Virus Infection, Covid19
- Main trialPhase 2
- “This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.”In the company’s words, NCT05017298 on ClinicalTrials.gov
- Other names
- Celltex-AdMSCs
Other drugs for Corona Virus Infection
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes1
Last 90 days- 16 NovStatus changed: Not yet recruiting to Unknown · ClinicalTrials.gov NCT05017298
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Unknown | 1 Nov 2024 | Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026